OnCo

No description yet: the sentence for this tag has not been written. 4 records carry it: 3 biomarkers, 1 person.

4 records
Germline BRCA1/2 pathogenic variant (gBRCAm)
BRCA1, BRCA2
A germline BRCA1 or BRCA2 variant is inherited and present in every cell, found by a blood test. It selects PARP inhibitors in breast, ovarian, pancreatic and prostate cancer and tells relatives they may carry it too.
HRD-positive (genomic instability score)
BRCA1, BRCA2
HRD-positive means the tumour's genome carries the scars of failed double-strand break repair (or a BRCA mutation), measured as a genomic instability score. In ovarian cancer it selects niraparib, and olaparib with bevacizumab, as first-line maintenance.
Talia Golan
Director, Pancreatic Cancer Center, Sheba Medical Center · Sheba Medical Center
Led POLO, the first biomarker-driven trial in pancreatic cancer, which brought olaparib to BRCA carriers.
Tumour (somatic or germline) BRCA1/2 mutation and HRR gene alterations
BRCA1, BRCA2
Tumour BRCA testing finds BRCA1/2 mutations in the cancer itself, whether inherited or acquired; wider panels add other repair genes such as ATM and PALB2. Ovarian and prostate cancer labels accept the tumour result for PARP inhibitors.

This tag as JSON · API